ATE466569T1 - Nasale verabreichung von metoclopramid zur behandlung der gastroparese - Google Patents

Nasale verabreichung von metoclopramid zur behandlung der gastroparese

Info

Publication number
ATE466569T1
ATE466569T1 AT01922935T AT01922935T ATE466569T1 AT E466569 T1 ATE466569 T1 AT E466569T1 AT 01922935 T AT01922935 T AT 01922935T AT 01922935 T AT01922935 T AT 01922935T AT E466569 T1 ATE466569 T1 AT E466569T1
Authority
AT
Austria
Prior art keywords
gastroparesis
treatment
metoclopramide
nasal administration
nasal
Prior art date
Application number
AT01922935T
Other languages
English (en)
Inventor
Laura Lehman
David Tierney
Anastassios Retzios
Michael Petrone
David Young
Carol Trapnell
Ruth Oliver
Original Assignee
Evoke Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evoke Pharma Inc filed Critical Evoke Pharma Inc
Application granted granted Critical
Publication of ATE466569T1 publication Critical patent/ATE466569T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT01922935T 2000-03-30 2001-03-30 Nasale verabreichung von metoclopramid zur behandlung der gastroparese ATE466569T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19318100P 2000-03-30 2000-03-30
PCT/US2001/010356 WO2001074350A1 (en) 2000-03-30 2001-03-30 Nasal administration of agents for the treatment of gastroparesis

Publications (1)

Publication Number Publication Date
ATE466569T1 true ATE466569T1 (de) 2010-05-15

Family

ID=22712552

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01922935T ATE466569T1 (de) 2000-03-30 2001-03-30 Nasale verabreichung von metoclopramid zur behandlung der gastroparese

Country Status (12)

Country Link
US (2) US6770262B2 (de)
EP (1) EP1274414B1 (de)
KR (1) KR20030004361A (de)
AT (1) ATE466569T1 (de)
AU (1) AU2001249684A1 (de)
CA (1) CA2403994C (de)
CY (1) CY1111396T1 (de)
DE (1) DE60142037D1 (de)
DK (1) DK1274414T3 (de)
ES (1) ES2346290T3 (de)
PT (1) PT1274414E (de)
WO (1) WO2001074350A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040192781A1 (en) * 2003-03-31 2004-09-30 Haley Eugene T. Method of administration for metoclopramide and pharmaceutical formulation therefor
US20050137265A1 (en) * 2003-03-31 2005-06-23 Haley Eugene T. Rapidly dissolving metoclopramide solid oral dosage and method thereof
US6979562B2 (en) * 2003-11-18 2005-12-27 Ultra Biotech Limited Methods and compositions for treating gastroparesis
WO2005065185A2 (en) * 2003-12-24 2005-07-21 Collegium Pharmaceuticals, Inc. Temperature-stable formulations, and methods of development thereof
MX2008004268A (es) * 2008-03-28 2009-09-28 Posi Visionary Solutions Llp Metoclopramida de liberacion prolongada de 24 horas.
MX2008004267A (es) * 2008-03-28 2009-09-28 Posi Visionary Solutions Llp Metoclopramida de liberacion prolongada de 12 horas.
US20130213393A1 (en) 2009-12-22 2013-08-22 Evoke Pharma, Inc. Nasal formulations of metoclopramide
DK2376075T3 (en) * 2008-12-22 2015-05-26 Evoke Pharma Inc Nasal formulations of metoclopramide
JP6051431B2 (ja) 2011-03-23 2016-12-27 ラクオリア創薬株式会社 消化管運動促進剤として機能する５−ｈｔ４受容体作動物質
PL2747561T3 (pl) * 2011-08-25 2018-11-30 Evoke Pharma, Inc. Leczenie objawów związanych z gastroparezą u osobników płci żeńskiej
US9833447B2 (en) * 2014-05-16 2017-12-05 Raqualia Pharma Inc. 5-HT4 receptor agonist for gastroparesis
CN104606136A (zh) * 2015-01-06 2015-05-13 中国人民解放军军事医学科学院毒物药物研究所 甲氧氯普胺鼻腔喷雾剂、其制备方法及用途
WO2018112061A1 (en) * 2016-12-15 2018-06-21 Evoke Pharma, Inc. Treatment of moderate and severe gastroparesis
US20200276139A1 (en) * 2017-09-11 2020-09-03 Evoke Pharma, Inc. Methods of intranasal metoclopramide dosing
US11786512B2 (en) 2019-09-23 2023-10-17 Slayback Pharma Llc Stable pharmaceutical compositions of dihydroergotamine mesylate

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4624965A (en) 1984-11-15 1986-11-25 Nastech Pharmaceutical Co., Inc. Novel method of administering anti-nausea and anti-emetic pharmaceutical agents and novel dosage forms containing same
US5578628A (en) * 1985-06-25 1996-11-26 Glaxo Group Limited Medicaments for the treatment of nausea and vomiting
US4729997A (en) 1985-10-15 1988-03-08 Nastech Pharmaceutical Co., Inc. Novel method of administering meclizine type pharmaceutical agents and novel dosage forms containing same
FR2640139A1 (fr) 1988-12-14 1990-06-15 Delagrange Laboratoires Application de benzamides substitues comme gastromoteurs
CH681690A5 (en) 1990-09-28 1993-05-14 Kali Chemie Pharma Gmbh New metoclopramide salt compsns. with no additives
US5576317A (en) 1994-12-09 1996-11-19 Pfizer Inc. NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
US5760086A (en) 1996-03-14 1998-06-02 Ribogene, Inc. Nasal administration of agents for treatment of delayed onset emesis

Also Published As

Publication number Publication date
US20020065321A1 (en) 2002-05-30
EP1274414B1 (de) 2010-05-05
KR20030004361A (ko) 2003-01-14
WO2001074350A1 (en) 2001-10-11
DE60142037D1 (de) 2010-06-17
ES2346290T3 (es) 2010-10-14
EP1274414A4 (de) 2007-08-22
AU2001249684A1 (en) 2001-10-15
EP1274414A1 (de) 2003-01-15
CY1111396T1 (el) 2015-08-05
CA2403994C (en) 2011-08-23
US20030059374A1 (en) 2003-03-27
US6770262B2 (en) 2004-08-03
PT1274414E (pt) 2010-08-10
CA2403994A1 (en) 2001-10-11
DK1274414T3 (da) 2010-08-30

Similar Documents

Publication Publication Date Title
CY1111396T1 (el) Ρινικη χορηγηση μετοκλοπραμιδης για την αγωγη της γαστροπαρεσης
EA200300776A1 (ru) Производные фенэтаноламина для лечения респираторных заболеваний
AU5584901A (en) Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease
DK0927161T3 (da) Substitueret cyklisk amin-metalloproteaseinhibitorer
EE200100487A (et) Uudsed ühendid ja kompositsioonid proteaasiinhibiitoritena
NO20024005D0 (no) Pteridinforbindelser for behandling av psoriasis
DK1263729T3 (da) Cykliske azaforbindelser til anvendelse til behandling af serotoninrealterede sygdomme
ATE301995T1 (de) Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen
ATE389395T1 (de) Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson
SE0100569D0 (sv) New compounds
DK1458393T3 (da) Substituerede diketopiperaziner som oxytocinantagonister
DE60130661D1 (de) Verwendung der 13-cis retinsäure zur behandlung von emphysemen
ATE202483T1 (de) Immuntolerante prothrombinkomplex-präparation
ATE363474T1 (de) Benzimidazole zur behandlung sexueller fehlfunktionen
NO20025405D0 (no) Modulatorer for TNF-alfa-signalisering
DE60044160D1 (de) Behandlung von Inkontinenz
EA200100930A1 (ru) Способ лечения хозл
EA200200948A1 (ru) Лечение псориаза
DE60015098D1 (de) 3-cyclopropylmethoxy-4-difluormethoxy-n-(3,5-dichlor-pyrid-4-yl)-benzamid zur behandlung von multipler sklerose
DE60114597D1 (de) Naphthamid-neurokinin antagonisten zur verwendung als medikamente
SE0004827D0 (sv) Therapeutic compounds
ATE536874T1 (de) Dreifache monoamin-wiederaufnahmehemmer zur behandlung von chronischen schmerzen
DE60330233D1 (de) Arsentherapie zur behandlung von autoimmunerkrankungen
ATE288254T1 (de) Methode zur behandlung von schlaganfall
DE60218726D1 (de) Verwendung von 4-oxo-butansäure derivaten zur behandlung der entzündung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1274414

Country of ref document: EP